Likewise, Keup and colleagues suggested that the use of novel agents to attack BC stem cells, like salinomycin and a new synthetic curcumin analog against Aldehyde Dehydrogenase 1 (ALDH1), could be promising in patients with ALDH1+ CTCs [27]. This evidence concerns the gene ALDH1A1 and breast cancer.